WELCOME TO The Biotechnology REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
AGC Biologics | May 14, 2020
AGC Biologics, a global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), will be participating in the first-ever BIO Digital event. BIO International Conference is holding its annual event virtually this year in order to safely connect industry experts amidst the COVID-19 global pandemic. The event, which takes place June 8 - 12, brings together capital, scientific and development expertise that is required to turn promising innovation into successful medicine....
AGC Biologics | May 22, 2020
AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO) for Biopharmaceuticals, has announced its partnership with Takara Bio.
The companies will partner in the fight against COVID-19 by collaborating on a prophylaxis DNA vaccine,...
AGC Biologics | June 03, 2020
AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced that it will partner with Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, on large-scale GMP production of a critical component of Novavax' coronavirus vaccine candidate, NVX-CoV2373. AGC Biologics will manufacture Matrix-M™, the adjuvant component of the vaccine, in order to enhan...
AGC Biologics | June 16, 2020
AGC Biologics, a global biopharmaceutical Contract Development Manufacturing Organization (CDMO), has announced it will be partnering with Saiba AG to manufacture a SARS-CoV-2 vaccine to protect against COVID-19. Saiba AG is a Swiss biotechnology company that specializes in the research and development of virus-like particle (VLP) vaccines for infectious and chronic diseases. Saiba AG is leveraging its patented Cucumber Mosaic Virus VLP platform technology to develop the SARS-CoV-2 vaccine. ...
CELL AND GENE THERAPY
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE